Double radiation attack on prostate cancer shows promise in early trial
NCT ID NCT04886986
First seen Apr 10, 2026 · Last updated May 25, 2026 · Updated 8 times
Summary
This early-phase study tests a combination of two targeted radiation drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs deliver radiation directly to cancer cells. The main goal is to find the safest dose and see how many patients experience a significant drop in PSA levels. About 20 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brooklyn Methodist Hospital - New York Presbyterian
Brooklyn, New York, 11215, United States
-
Weill Cornell Medicine New York Presbyterian
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.